Powering Hearts
Beat to Beat

Q:  The Assert-IQ ICM is proudly marketed by Abbott as the world’s longest-lasting Bluetooth^® functionality ICM “with no compromises.” What exactly does “no compromises” mean?

A: When we designed the overall system, we aimed to be number one in the market. We were mindful that the functionality of competitive ICM systems could be limited in exchange for additional longevity. Saving battery life by limiting patient app settings or using manual Bluetooth^® functionality can prevent real-time syncing between the smartphone and device. We designed the Assert-IQ ICM to achieve extended battery longevity, without limiting any functionality or connectivity, enabling continuously monitoring without compromises.

Q:  How does the Assert-IQ EL+ ICM 6-year battery longevity compare to other ICMs?

A: There’s no comparison. It is in a league of its own. In published estimations, our technology continues to be very clearly on top overall, while the competition still needs to limit functionality to achieve their maximum labeled longevity.

Q:  How does the Assert-IQ EL+ ICM compare in size and implant procedure to others on the market?

A: As always, when developing life-saving technology, the overall workflow of procedure is top of mind. An incision and insertion tool are still used during the procedure. The only difference is a small increase in device thickness – just one millimeter – which does not change the procedure but doubles the battery longevity. The feedback we’ve received from patients is that they’re still comfortable with the device. Overall, one millimeter for an extra three years is a good tradeoff. 

Q:  It sounds like it truly does not compromise any features for long-term monitoring. What does this mean for long-term monitoring of AF?

A: Some important feedback we’ve received from patients is the peace of mind they feel when they’re continuously monitored. AF can be a chronic challenge. Some patients may need to be monitored pre- and post-ablation. They’re more comfortable when they remain connected to the healthcare system where there is a maintained and uninterrupted workflow in place to help manage their AF. That is what I perceive the Assert-IQ ICM’s longevity means to patients.

Q:  Is there any data out there that supports Assert-IQ ICM’s battery performance?

Q:  Where do you see insertable cardiac monitoring technology going in the future?

A: It’s incredibly promising. We see the system expanding scope into additional indications. There is potential for ICMs to monitor heart failure and uncontrolled hypertension. When devices can play a big role in early detection, that plays a big role in patient outcomes. We have an incredible platform in the Assert-IQ ICM to build into the future.

Q:  How are you leading teams within Abbott to prepare for the future of ICMs?

A: It always starts with the patient. With our primary focus to deeply understand and address unmet clinical needs, we immerse ourselves in the real-world challenges of our customers. That helps engineering develop meaningful solutions throughout the organization. Continuous learning and cross-functional collaboration address the healthcare landscape challenges that are constantly evolving. This is how we deliver exceptional outcomes for patients.